BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 25562382)

  • 1. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
    Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
    Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
    Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
    Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
    Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
    Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
    Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of
    Berwouts D; Madani I; Duprez F; Olteanu AL; Vercauteren T; Boterberg T; Deron P; Bonte K; Huvenne W; De Neve W; Goethals I
    Head Neck; 2017 Nov; 39(11):2264-2275. PubMed ID: 28833829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation dose escalation based on FDG-PET driven dose painting by numbers in oropharyngeal squamous cell carcinoma: a dosimetric comparison between TomoTherapy-HA and RapidArc.
    Differding S; Sterpin E; Hermand N; Vanstraelen B; Nuyts S; de Patoul N; Denis JM; Lee JA; Grégoire V
    Radiat Oncol; 2017 Mar; 12(1):59. PubMed ID: 28335778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.
    Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y
    Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
    Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation analysis of [
    Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
    Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
    Bruine de Bruin L; Bollineni VR; Wachters JE; Schuuring E; van Hemel BM; van der Wal JE; Slagter-Menkema L; de Bock GH; Steenbakkers RJ; Langendijk JA; Pruim J; van der Laan BF; Halmos GB
    Radiother Oncol; 2015 Oct; 117(1):106-12. PubMed ID: 26250803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer.
    Schuetz M; Schmid MP; Pötter R; Kommata S; Georg D; Lukic D; Dudczak R; Kletter K; Dimopoulos J; Karanikas G; Bachtiary B
    Acta Oncol; 2010 Oct; 49(7):941-7. PubMed ID: 20831481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation.
    Schwartz DL; Ford EC; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellen B; Mattes D; Kinahan P; Meyer J; Phillips M; Leblanc M; Krohn K; Eary J; Laramore GE
    Head Neck; 2005 Jun; 27(6):478-87. PubMed ID: 15772953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose prescription and treatment planning based on FMISO-PET hypoxia.
    Toma-Dasu I; Uhrdin J; Antonovic L; Dasu A; Nuyts S; Dirix P; Haustermans K; Brahme A
    Acta Oncol; 2012 Feb; 51(2):222-30. PubMed ID: 21871003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT during concomitant chemo radiotherapy for esophageal cancer: Reducing target volumes to deliver higher radiotherapy doses.
    Nkhali L; Thureau S; Edet-Sanson A; Doyeux K; Benyoucef A; Gardin I; Michel P; Vera P; Dubray B
    Acta Oncol; 2015 Jun; 54(6):909-15. PubMed ID: 25417733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.